These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 33691259)

  • 1. Pharmacological approaches to cystic fibrosis.
    Bandiera T; Galietta LJV
    Eur J Med Chem; 2021 Apr; 216():113240. PubMed ID: 33691259
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug bests cystic-fibrosis mutation.
    Ledford H
    Nature; 2012 Feb; 482(7384):145. PubMed ID: 22318583
    [No Abstract]   [Full Text] [Related]  

  • 3. Cystic fibrosis: CFTR modulators and their mechanism of action.
    Nieddu E
    Curr Pharm Des; 2013; 19(19):3474-5. PubMed ID: 23331031
    [No Abstract]   [Full Text] [Related]  

  • 4. Novel pharmacological strategies to treat cystic fibrosis.
    Hanrahan JW; Sampson HM; Thomas DY
    Trends Pharmacol Sci; 2013 Feb; 34(2):119-25. PubMed ID: 23380248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cystic fibrosis transmembrane conductance regulator biomarkers in 'real life': can we evaluate individual efficacy of cystic fibrosis transmembrane conductance regulator therapy?
    van Koningsbruggen-Rietschel S; Naehrlich L
    Ther Adv Respir Dis; 2015 Aug; 9(4):198-200. PubMed ID: 26175480
    [No Abstract]   [Full Text] [Related]  

  • 6. Personalized medicine. New cystic fibrosis drug offers hope, at a price.
    Kaiser J
    Science; 2012 Feb; 335(6069):645. PubMed ID: 22323790
    [No Abstract]   [Full Text] [Related]  

  • 7. Excitement mounts for first disease-modifying cystic fibrosis drugs.
    Opar A
    Nat Rev Drug Discov; 2011 Jul; 10(7):479-80. PubMed ID: 21720393
    [No Abstract]   [Full Text] [Related]  

  • 8. Correctors of the basic trafficking defect of the mutant F508del-CFTR that causes cystic fibrosis.
    Birault V; Solari R; Hanrahan J; Thomas DY
    Curr Opin Chem Biol; 2013 Jun; 17(3):353-60. PubMed ID: 23711435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New pharmaceutical approaches to the treatment of cystic fibrosis.
    Delaney SJ; Wainwright BJ
    Nat Med; 1996 Apr; 2(4):392-3. PubMed ID: 8597941
    [No Abstract]   [Full Text] [Related]  

  • 10. Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies.
    Antoniu SA
    Expert Opin Investig Drugs; 2011 Mar; 20(3):423-5. PubMed ID: 21303308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction by antitumoral drugs of proteins that functionally complement CFTR: a novel therapy for cystic fibrosis?
    Lallemand JY; Stoven V; Annereau JP; Boucher J; Blanquet S; Barthe J; Lenoir G
    Lancet; 1997 Sep; 350(9079):711-2. PubMed ID: 9291908
    [No Abstract]   [Full Text] [Related]  

  • 12. Cystic fibrosis foundation opens drug discovery lab.
    Trivedi BP
    Science; 2016 Sep; 353(6305):1194-5. PubMed ID: 27634505
    [No Abstract]   [Full Text] [Related]  

  • 13. Targeting CFTR: how to treat cystic fibrosis by CFTR-repairing therapies.
    Amaral MD
    Curr Drug Targets; 2011 May; 12(5):683-93. PubMed ID: 21039334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cystic Fibrosis: Translating Molecular Mechanisms into Effective Therapies.
    Jennings MT; Flume PA
    Ann Am Thorac Soc; 2018 Aug; 15(8):897-902. PubMed ID: 29812963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PharmGKB summary: very important pharmacogene information for CFTR.
    McDonagh EM; Clancy JP; Altman RB; Klein TE
    Pharmacogenet Genomics; 2015 Mar; 25(3):149-56. PubMed ID: 25514096
    [No Abstract]   [Full Text] [Related]  

  • 16. Cystic fibrosis: five years beyond the gene.
    Porteous DJ
    J Inherit Metab Dis; 1995; 18(4):491-4. PubMed ID: 7494406
    [No Abstract]   [Full Text] [Related]  

  • 17. Reshma Kewalramani.
    Mullard A
    Nat Rev Drug Discov; 2019 Nov; 18(12):896-897. PubMed ID: 31780855
    [No Abstract]   [Full Text] [Related]  

  • 18. Rescuing protein conformation: prospects for pharmacological therapy in cystic fibrosis.
    Gelman MS; Kopito RR
    J Clin Invest; 2002 Dec; 110(11):1591-7. PubMed ID: 12464661
    [No Abstract]   [Full Text] [Related]  

  • 19. Cystic fibrosis: a multiple exocrinopathy caused by dysfunctions in a multifunctional transport protein.
    Schwiebert EM; Benos DJ; Fuller CM
    Am J Med; 1998 Jun; 104(6):576-90. PubMed ID: 9674722
    [No Abstract]   [Full Text] [Related]  

  • 20. Molecular modelling approaches for cystic fibrosis transmembrane conductance regulator studies.
    Odolczyk N; Zielenkiewicz P
    Int J Biochem Cell Biol; 2014 Jul; 52():39-46. PubMed ID: 24735712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.